Lineage Cell Therapeutics (LCTX) Reports In-Line Q1 EPS

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $695.33 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on IMAX Corporation (IMAX), Highlights 'The Odyssey' Potential
• BMO Capital Reiterates Outperform Rating on CMS Energy (CMS)